These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 32504503)

  • 41. Disease mechanisms as subtypes: Microbiome.
    Bonvegna S; Cilia R
    Handb Clin Neurol; 2023; 193():107-131. PubMed ID: 36803806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson's Disease.
    Guo TT; Zhang Z; Sun Y; Zhu RY; Wang FX; Ma LJ; Jiang L; Liu HD
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The gut microbiota-brain axis, psychobiotics and its influence on brain and behaviour: A systematic review.
    Barrio C; Arias-Sánchez S; Martín-Monzón I
    Psychoneuroendocrinology; 2022 Mar; 137():105640. PubMed ID: 34942539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.
    Liu J; Xu F; Nie Z; Shao L
    Front Cell Infect Microbiol; 2020; 10():570658. PubMed ID: 33194809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease.
    Baizabal-Carvallo JF; Alonso-Juarez M
    Neuroscience; 2020 Apr; 432():160-173. PubMed ID: 32112917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies.
    Zhang X; Tang B; Guo J
    Transl Neurodegener; 2023 Dec; 12(1):59. PubMed ID: 38098067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson's Disease.
    Kulcsarova K; Bang C; Berg D; Schaeffer E
    J Parkinsons Dis; 2023; 13(7):1079-1106. PubMed ID: 37927277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A nutritional approach to microbiota in Parkinson's disease.
    Uyar GÖ; Yildiran H
    Biosci Microbiota Food Health; 2019; 38(4):115-127. PubMed ID: 31763115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
    Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
    Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Environmental neurotoxicants and inflammasome activation in Parkinson's disease - A focus on the gut-brain axis.
    Johnson AM; Ou ZA; Gordon R; Saminathan H
    Int J Biochem Cell Biol; 2022 Jan; 142():106113. PubMed ID: 34737076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Microbiome-Brain Communication on Neuroinflammation and Neurodegeneration.
    Stolzer I; Scherer E; Süß P; Rothhammer V; Winner B; Neurath MF; Günther C
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease.
    van Kessel SP; El Aidy S
    J Parkinsons Dis; 2019; 9(s2):S359-S370. PubMed ID: 31609701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Linking circadian rhythms to microbiome-gut-brain axis in aging-associated neurodegenerative diseases.
    Cheng WY; Ho YS; Chang RC
    Ageing Res Rev; 2022 Jun; 78():101620. PubMed ID: 35405323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis.
    Manfready RA; Goetz CG; Keshavarzian A
    Int Rev Neurobiol; 2022; 167():81-99. PubMed ID: 36427960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut Microbiota and Neurologic Diseases and Injuries.
    Tyler Patterson T; Grandhi R
    Adv Exp Med Biol; 2020; 1238():73-91. PubMed ID: 32323181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Probiotics for Parkinson's Disease.
    Gazerani P
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkinson's disease and the gastrointestinal microbiome.
    Lubomski M; Tan AH; Lim SY; Holmes AJ; Davis RL; Sue CM
    J Neurol; 2020 Sep; 267(9):2507-2523. PubMed ID: 31041582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Hill-Burns EM; Debelius JW; Morton JT; Wissemann WT; Lewis MR; Wallen ZD; Peddada SD; Factor SA; Molho E; Zabetian CP; Knight R; Payami H
    Mov Disord; 2017 May; 32(5):739-749. PubMed ID: 28195358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.